

MIXiii Health-Tech.IL – OIS Preliminary Program – March 6, 2024



Time	Function												
11:45-11:50	Welcome Remarks <i>Daphne Haim-Langford</i> , PhD, Chairperson, Founder & CEO, Tarsier Pharma												
11:50-12:05	Year in Review <i>Nahum Ferera</i> , CEO and Co-Founder, EyeYon Medical												
12:05-12:45	Company Presentations: Pre-Clinical Stage Moderator: <i>Almog Aley Raz</i> , CEO & VP R&D, CorNeat Vision <table border="1" data-bbox="338 657 1056 1008" style="margin-top: 10px;"> <tbody> <tr> <td>12:05</td> <td>OPHTIMED RX</td> </tr> <tr> <td>12:11</td> <td>BLINK ENERGY</td> </tr> <tr> <td>12:17</td> <td>SUPRA MEDICAL</td> </tr> <tr> <td>12:23</td> <td>OPHRX</td> </tr> <tr> <td>12:29</td> <td>PRECISE BIO</td> </tr> <tr> <td>12:35</td> <td>I-OPTSENS</td> </tr> </tbody> </table>	12:05	OPHTIMED RX	12:11	BLINK ENERGY	12:17	SUPRA MEDICAL	12:23	OPHRX	12:29	PRECISE BIO	12:35	I-OPTSENS
12:05	OPHTIMED RX												
12:11	BLINK ENERGY												
12:17	SUPRA MEDICAL												
12:23	OPHRX												
12:29	PRECISE BIO												
12:35	I-OPTSENS												
12:45-13:15	Panel Discussion: Pre-Launch Moderator: <i>Daphne Haim-Langford, PhD</i> , Chairperson, Founder & CEO, Tarsier Pharma Panelists: A Moment Before Launch, Moved from The Post Launch Session to Balance <i>Rami Skaliter, PhD</i> , CEO CellCure Neurosciences <i>Elad Kedar</i> , CEO, Orasis Pharmaceuticals <i>Jacky Hochner</i> , CEO, MIKAJAKI SA <i>Nikolai Kunicher PhD</i> , MBA, CEO , NeuroTrigger Ltd.												

1 *Program subject to changes – updated 22.02.2024

MIXiii Health-Tech.IL – OIS Preliminary Program – March 6, 2024



13:15-13:30	<i>Itay Mayer</i> , VP, Managing Director Vision, Lumenis												
13:30-14:30	Lunch												
14:30-15:10	<p>Company Presentations: Clinical Stage Moderator: Dana Rabinovitch, PhD, Co-Founder and CEO, OphtiMed Rx</p> <table border="1" data-bbox="338 558 999 959"> <tr> <td>14:30</td> <td>DIAGNOSTEAR</td> </tr> <tr> <td>14:36</td> <td>TARSIER PHARMA</td> </tr> <tr> <td>14:42</td> <td>EVERADS THERAPY</td> </tr> <tr> <td>14:48</td> <td>CORNEAT VISION</td> </tr> <tr> <td>14:54</td> <td>CELLCURE NEUROSCIENCES</td> </tr> <tr> <td>15:00</td> <td>EYAYON MEDICAL – ENDOART</td> </tr> </table>	14:30	DIAGNOSTEAR	14:36	TARSIER PHARMA	14:42	EVERADS THERAPY	14:48	CORNEAT VISION	14:54	CELLCURE NEUROSCIENCES	15:00	EYAYON MEDICAL – ENDOART
14:30	DIAGNOSTEAR												
14:36	TARSIER PHARMA												
14:42	EVERADS THERAPY												
14:48	CORNEAT VISION												
14:54	CELLCURE NEUROSCIENCES												
15:00	EYAYON MEDICAL – ENDOART												
15:10-15:25	<i>Yaacov Michlin</i> , CEO, BioLight Life Sciences Ltd. interviews Laurent Attias , Head Corporate Development, Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)												
15:25-15:55	<p>Unlocking Success: Commercialization Tips in Ophthalmology – Insights from An Industry Leader <i>Daphne Haim-Langford, PhD</i>, Chairperson, Founder & CEO, Tarsier Pharma interviews Susan Benton, President, Théa Group</p>												

2 *Program subject to changes – updated 22.02.2024

MIXiii Health-Tech.IL – OIS Preliminary Program – March 6, 2024



<p>15:55-16:30</p>	<p>Panel Discussion: Post-launch Moderator: Prof. Anat Loewenstein, MD, MHA, Chair, Department of Ophthalmology, Tel Aviv Medical Center Panelists: <i>Daria Lemann-Blumental</i>, CEO, BELKIN Vision <i>Nir Israeli</i>, CEO, Sanoculis <i>Yoram Gonen</i>, CEO, Hanita Lenses <i>Nahum Ferera</i>, CEO and Co-Founder, EyeYon Medical <i>Ran Yam</i>, CEO & Co-Founder, NovaSight Ltd.</p>														
<p>16:30-17:10</p>	<p>Company Presentations: Post Approval Stage Moderator: Barak Azmon, MD, Co-Founder & CEO, Notal Vision</p> <table border="1" data-bbox="338 792 999 1243"> <tr> <td>16:30</td> <td>SANOCULIS</td> </tr> <tr> <td>16:36</td> <td>MIKAJAKI, SA</td> </tr> <tr> <td>16:42</td> <td>PERIPHEREX</td> </tr> <tr> <td>16:48</td> <td>BELKIN VISION</td> </tr> <tr> <td>16:54</td> <td>EYAYON – HYPER CL</td> </tr> <tr> <td>17:00</td> <td>NOVA SIGHT</td> </tr> <tr> <td>17:06</td> <td>NEURO TRIGGER LTD.</td> </tr> </table>	16:30	SANOCULIS	16:36	MIKAJAKI, SA	16:42	PERIPHEREX	16:48	BELKIN VISION	16:54	EYAYON – HYPER CL	17:00	NOVA SIGHT	17:06	NEURO TRIGGER LTD.
16:30	SANOCULIS														
16:36	MIKAJAKI, SA														
16:42	PERIPHEREX														
16:48	BELKIN VISION														
16:54	EYAYON – HYPER CL														
17:00	NOVA SIGHT														
17:06	NEURO TRIGGER LTD.														

3 *Program subject to changes – updated 22.02.2024

MIXiii Health-Tech.IL – OIS Preliminary Program – March 6, 2024



17:10-17:30	Panel: Past and Future in Ophthalmology Moderator: Prof. Anat Loewenstein, MD, MHA , Chair, Department of Ophthalmology, Tel Aviv Medical Center Prof. Itay Chowers , Chairman Department of Ophthalmology, Hadassah Medical Center Dr. Yaniv Barkana , Co-founder at I-OPtSens, CMO at Galimedix Prof. Guy Kleinman , Chairman, Ophthalmology Department Wolfson Medical Center
17:30-18:00	Panel Discussion: Investors Moderator: Daria Lemann-Blumental, CEO, BELKIN Vision Panelists: Michal Geva , Co-Founder and Managing Partner, Triventures Limin Wang, PhD , Regional General Manager, Rimonci Capital Yaacov Michlin , CEO, BioLight Life Sciences Ltd and Chairman of MIXIII Health-Tech.IL Assaf Barnea , CEO, Sanara Ventures